Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2007-10-02
2007-10-02
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C536S028500, C536S028510, C536S028520, C549S511000, C546S113000, C514S009100, C514S011400, C514S449000, C514S459000, C514S460000
Reexamination Certificate
active
11082130
ABSTRACT:
Methods are provided for treating hematological disorders by inhibition of DNA hypomethylation and histone deacetylase. Such disorders include, for example, acute promyelocytic leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, myelodysplastic syndromes, and sickle cell anemia. The methods comprise: administering to a patient suffering from the disease a therapeutically effective amount of a DNA methylation inhibitor such as a cysteine analog such as decitabine, in combination with an effective amount of histone deacetylase inhibitor such as hydroxamic acid, cyclic peptide, benzamide, butyrate, and depudecin.
REFERENCES:
patent: 4690918 (1987-09-01), Beppu et al.
patent: 5283383 (1994-02-01), Boyd et al.
patent: 5736531 (1998-04-01), Von Borstel et al.
patent: 5968914 (1999-10-01), Von Borstel et al.
patent: 6110697 (2000-08-01), Dulski et al.
patent: 6613753 (2003-09-01), Rubinfeld et al.
patent: 6905669 (2005-06-01), DiMartino
patent: 2002/0114809 (2002-08-01), Rubinfeld et al.
patent: 2002/0136709 (2002-09-01), Zahner et al.
patent: 2003/0039689 (2003-02-01), Chen et al.
patent: 2003/0108588 (2003-06-01), Chen et al.
patent: 2003/0147813 (2003-08-01), Lyons
patent: 2003/0158598 (2003-08-01), Ashton et al.
patent: 2003/0229047 (2003-12-01), Joshi-Hangal et al.
patent: 2004/0019036 (2004-01-01), Robin et al.
patent: 269077 (1990-08-01), None
patent: 1922702 (1969-11-01), None
patent: 2105468 (1971-11-01), None
patent: 0286958 (1988-10-01), None
patent: 05219974 (1993-08-01), None
patent: 2002223753 (2002-08-01), None
patent: 2002370939 (2002-12-01), None
patent: 2003310293 (2003-11-01), None
patent: WO93/01202 (1993-01-01), None
patent: WO94/26761 (1994-11-01), None
patent: WO94/27632 (1994-12-01), None
patent: WO96/40165 (1996-12-01), None
patent: WO98/55449 (1998-12-01), None
patent: WO99/01118 (1999-01-01), None
patent: WO 00/23112 (2000-04-01), None
patent: WO 00/40269 (2000-07-01), None
patent: WO 00/74634 (2000-12-01), None
patent: WO 01/79164 (2001-10-01), None
patent: WO 02/47611 (2002-06-01), None
patent: WO 02/053138 (2002-07-01), None
patent: WO 02/057425 (2002-07-01), None
patent: WO 02/069903 (2002-09-01), None
patent: WO 02/076486 (2002-10-01), None
patent: WO 02/085400 (2002-10-01), None
patent: WO 03/020252 (2003-03-01), None
patent: WO 03/026574 (2003-04-01), None
patent: WO 03/046190 (2003-06-01), None
patent: WO 03/065995 (2003-08-01), None
patent: WO 03/076593 (2003-09-01), None
patent: WO 03/076594 (2003-09-01), None
patent: WO 2003/087774 (2003-10-01), None
patent: WO 03/092623 (2003-11-01), None
patent: WO 2004/009023 (2004-01-01), None
Baylin, S.B. et al., “Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia”,Cancer Res., (1998), 72:141-196.
Cameron, E.E., et al., “Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer”,Nature Genetics, (Jan. 1999), 21:103-107.
Cinar, B. et al., “Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line”,Cancer Research, (Oct. 1, 2001), 61:7310-7317.
Coffee, B. et al., “Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells”,Nature Genetics, (1999), 22:98-101.
Daskalakis, M. et al., “Expression of a Hypermethylated and Silenced P15/INK4B Gene in a Subgroup of MDS Patients is Restored by Treatment With The Methylation Inhibitor 5-AZA-2′-Deoxycytidine”, AbstractsLeukemia Research, (2001) Suppl. No. 1:S16-S17.
Endres, M. et al., “DNA Methyltransferase Contributes to Delayed Ischemic Brain Injury”,The Journal of Neuroscience, (2000), 20(9):3175-3181.
Esteller, M. et al., “A Gene Hypermethylation Profile of Human Cancer”,Cancer Research(Apr. 15, 2001), 61:3225-3229.
Esteller, M., “CpG Island Hypermethylation and Tumor Suppressor Genes: A Booming Present, A Brighter Future”,Oncogene, (2002), 21:5427-5440.
Esteller, M., “Epigenetic Lesions Causing Genetic Lesions in Human Cancer: Promoter Hypermethylation of DNA Repair Genes”,European Journal of Cancer, (2000), 36:2294-2300.
Gagnon, J. et al., “Interaction of 5-aza-2′-deoxycytidine and Depsipeptide on Antineoplastic Activity and Activation of 14-3-3σ, E-Cadherin And Tissue Inhibitor of Metalloproteinase 3 Expression in Human Breast Carcinoma Cells”,Anti-Cancer Drugs, (2003), 14(3):193-202.
Goffin, J. et al., “DNA Methyltransferase Inhibitors-State of the Art”,Annals of Oncology, (2002) 13:1699-1716.
Guan, R.J. et al., “Drg-1 as differentiation-related putative metastatic suppressor gene in human colon cancer”,Cancer Research, (Feb. 2000), 60:749-755.
Jones, P.A. et al., “The Fundamental Role of Epigenetic Events in Cancer,”Nature Reviews/Genetics, (2002), 3:415-428.
Jones, P.A. et al., “The Role of DNA Methylation in Cancer”,Advances in Cancer Research, (1990), 54:1-23.
Jones, P.A., “DNA Methylation And Cancer”,Oncogene, (2002), 21:5358-5360.
Karpf, A.R. et al., “Reactivating The Expression of Methylation Silenced Genes in Human Cancer,”Oncogene, (2002), 21:5496-5503.
Kijima, M. et al., “Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase”,J. Biol. Chem., (Oct. 25, 1993), 268(30):22429-22435.
Koshy, M. et al., “2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia”, Clinical Observations, Interventions, and Therapeutic Trials,Blood, (Oct. 1, 2000), 96(7):2379-2384.
La Rosee, P. et al., “In Vitro Efficacy of Combined Treatment Depends on the Underlying Mechanism of Resistance in Imatinib-Resistant Bcr-Abl positive Cell Lines”,Blood First Edition Paper, prepublished online (2003) DOI 10.1182/blood-2003-04-1074, pp. 1-39.
Marks, P.A. et al., “Histone Deacetylase Inhibitors: Inducers of Differentiation of Apoptosis of Transformed Cells” A Review,Journal of the National Cancer Institute, (Aug. 2, 2000), 92(15):1210-1216.
Nakayama, T. et al., “Epigenetic regulation of androgen receptor gene expression in human prostate cancers”,Lab. Invest., (Dec. 2000), 80(12):1789-1796.
Nephew, K.P. et al., “Epigenetic Gene Silencing in Cancer Initiation And Progression”,Cancer Letters, (2003), 190:125-133.
Paz, M.F. et al., “A Systematic Profile of DNA Methylation in Human Cancer Cell Lines”,Cancer Research, (Mar. 1, 2003), 63:1114-1121.
Primeau, M. et al., “Synergistic Antineoplastic Action of DNA Methylation Inhibitor 5-AZA-2′-Deoxycytidine and Histone Deacetylase Inhibitor Depsipeptide on Human Breast Carcinoma Cells”,Int. J. Cancer, (2003), 103:177-184.
Saito, A. et al., “A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo Antitumor activity against Human Tumors”,Proc. Natl.Acad. Sci. USA, (Apr. 1999), 96:4592-4597.
Santini, V. et al., “Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic Implications”,Annals of Internal Medicine, (Apr. 3, 2001), 134:573-586.
Schrump, D.S. et al., “Phase I Study of Sequential Deoxyazacytidine/Depsipeptide Infusion in Patients With Malignancies Involving Lungs or Pleura”,Clinical Lung Cancer, (2002), 186-192.
Shaker, S., et al., “Preclinical Evaluation of Antineoplastic Activity of Inhibitors of DNA Methylation (5-aza-2′-deoxycytidine) and Histone Deacetylation (Trichostatin A, Depsipeptide) in Combination Against Myeloid Leukemic Cells”,LeukemiaResearch, (2003), 27:437-444.
Sheikhnejad, G., et al., “Mechanism of Inhibition of DNA (Cytosine C5)-Methyltransferases by Oligodeoxyribonucleotides Containing 5, 6-Dihydro-5-Azacytosine”,J. Mol. Biol., (1999), 285:2021-2034.
Smiraglia, D.J. et al., “The Study of Aberrant Methylation in Cancer via Restriction Landmark Genomic Scanning
Kam Chih-Min
SuperGen, Inc.
Wilson Sonsini Goodrich & Rosati
LandOfFree
Methods for treating hematological disorders through... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating hematological disorders through..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating hematological disorders through... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3896985